Merriman Curhan Ford initiates coverage on Amylin Pharmaceuticals (Nasdaq: AMLN) with a Buy rating, citing increasing likelihood of approval of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE